• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer.

作者信息

Pannuti F, Martoni A, Di Marco A R, Piana E, Saccani F, Becchi G, Mattioli G, Barbanti F, Marra G A, Persiani W, Cacciari L, Spagnolo F, Palenzona D, Rocchetta G

出版信息

Eur J Cancer (1965). 1979 Apr;15(4):593-601. doi: 10.1016/0014-2964(79)90097-5.

DOI:10.1016/0014-2964(79)90097-5
PMID:86447
Abstract
摘要

相似文献

1
Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer.两种不同高剂量醋酸甲羟孕酮（MAP）治疗转移性乳腺癌的前瞻性随机临床试验。
Eur J Cancer (1965). 1979 Apr;15(4):593-601. doi: 10.1016/0014-2964(79)90097-5.
2
High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation.高剂量醋酸甲羟孕酮（MPA）治疗转移性乳腺癌：剂量反应评估
Tumori. 1978 Apr 30;64(2):143-9. doi: 10.1177/030089167806400204.
3
[Results of the treatment of patients with advanced breast with large doses of medroxyprogesterone acetate].[大剂量醋酸甲羟孕酮治疗晚期乳腺癌患者的结果]
Pol Tyg Lek. 1988 May 30;43(22):712-4.
4
Weekly low-dose doxorubicin with or without high-dose medroxyprogesterone acetate as secondary treatment in metastatic breast cancer--a randomized trial.转移性乳腺癌二线治疗中每周低剂量阿霉素联合或不联合高剂量醋酸甲羟孕酮的随机试验
Acta Oncol. 1988;27(3):297-9. doi: 10.3109/02841868809093543.
5
Therapeutic activity of medroxyprogesterone acetate in metastatic breast cancer: a correlation between estrogen receptors and various dosages.醋酸甲羟孕酮在转移性乳腺癌中的治疗活性：雌激素受体与不同剂量之间的相关性。
Recent Results Cancer Res. 1984;91:243-7. doi: 10.1007/978-3-642-82188-2_34.
6
An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancer.对晚期乳腺癌女性患者进行大剂量醋酸甲羟孕酮（MPA）治疗的评估。
Br J Cancer. 1984 Sep;50(3):363-6. doi: 10.1038/bjc.1984.184.
7
Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.低剂量与高剂量醋酸甲羟孕酮用于绝经后晚期乳腺癌患者诱导治疗的随机试验
J Clin Oncol. 1984 May;2(5):414-9. doi: 10.1200/JCO.1984.2.5.414.
8
Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancer.转移性乳腺癌联合激素治疗（MAP + TAM）的临床试验。
Chemioterapia. 1984 Aug;3(4):211-5.
9
Hormone therapy in advanced breast cancer: high dose medroxyprogesterone acetate (MAP) vs tamoxifen (TMX). Preliminary results.晚期乳腺癌的激素治疗：大剂量醋酸甲羟孕酮（MAP）与他莫昔芬（TMX）对比。初步结果。
Eur J Cancer (1965). 1980;Suppl 1:93-8.
10
[High dose medroxyprogesterone acetate in metastatic breast cancer. Comparative clinical, pharmacokinetic and pharmacodynamic data of different forms of administration].[大剂量醋酸甲羟孕酮治疗转移性乳腺癌。不同给药方式的临床、药代动力学和药效学对比数据]
Onkologie. 1982 Aug;5 Suppl:13-6.

引用本文的文献

1
Hormone Signaling in Breast Development and Cancer.乳腺发育与癌症中的激素信号传导
Adv Exp Med Biol. 2025;1464:279-307. doi: 10.1007/978-3-031-70875-6_15.
2
Type 1 Nuclear Receptor Activity in Breast Cancer: Translating Preclinical Insights to the Clinic.乳腺癌中的1型核受体活性：将临床前见解转化为临床应用
Cancers (Basel). 2021 Oct 3;13(19):4972. doi: 10.3390/cancers13194972.
3
Signaling pathways and steroid receptors modulating estrogen receptor α function in breast cancer.信号通路和甾体受体调节乳腺癌中雌激素受体 α 的功能。
Genes Dev. 2018 Sep 1;32(17-18):1141-1154. doi: 10.1101/gad.316646.118.
4
Deciphering the divergent roles of progestogens in breast cancer.解析孕激素在乳腺癌中的不同作用。
Nat Rev Cancer. 2017 Jan;17(1):54-64. doi: 10.1038/nrc.2016.116. Epub 2016 Nov 25.
5
Mechanisms of oestrogen receptor (ER) gene regulation in breast cancer.乳腺癌中雌激素受体（ER）基因调控的机制。
Eur J Endocrinol. 2016 Jul;175(1):R41-9. doi: 10.1530/EJE-16-0124. Epub 2016 Feb 16.
6
Combined effect of navelbine with medroxyprogesterone acetate against human breast carcinoma MCF-7 cells in vitro.去甲长春花碱与醋酸甲羟孕酮联合对人乳腺癌MCF-7细胞的体外作用
Br J Cancer. 1998 Jun;77(11):1737-43. doi: 10.1038/bjc.1998.291.
7
Modulation of adriamycin resistance in human breast carcinoma MCF-7 cells in vitro and in vivo by medroxyprogesterone acetate.醋酸甲羟孕酮对人乳腺癌MCF-7细胞体外及体内阿霉素耐药性的调节作用
Jpn J Cancer Res. 1994 May;85(5):542-9. doi: 10.1111/j.1349-7006.1994.tb02393.x.
8
An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancer.对晚期乳腺癌女性患者进行大剂量醋酸甲羟孕酮（MPA）治疗的评估。
Br J Cancer. 1984 Sep;50(3):363-6. doi: 10.1038/bjc.1984.184.
9
Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients.
Cancer Chemother Pharmacol. 1983;11(1):19-22. doi: 10.1007/BF00257410.
10
Weekly low dose doxorubicin monotherapy in metastatic breast cancer resistant to previous hormonal and cytostatic treatment.每周低剂量阿霉素单药治疗对先前激素和细胞抑制治疗耐药的转移性乳腺癌。
Breast Cancer Res Treat. 1985;6(1):89-93. doi: 10.1007/BF01806014.